JP2015509917A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015509917A5 JP2015509917A5 JP2014552215A JP2014552215A JP2015509917A5 JP 2015509917 A5 JP2015509917 A5 JP 2015509917A5 JP 2014552215 A JP2014552215 A JP 2014552215A JP 2014552215 A JP2014552215 A JP 2014552215A JP 2015509917 A5 JP2015509917 A5 JP 2015509917A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- compound
- atherosclerosis
- treatment
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 claims 4
- 206010065558 Aortic arteriosclerosis Diseases 0.000 claims 2
- 208000002223 abdominal aortic aneurysm Diseases 0.000 claims 2
- 208000007474 aortic aneurysm Diseases 0.000 claims 2
- 201000001962 aortic atherosclerosis Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- TYEYBOSBBBHJIV-UHFFFAOYSA-N 2-oxobutanoic acid Chemical compound CCC(=O)C(O)=O TYEYBOSBBBHJIV-UHFFFAOYSA-N 0.000 claims 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261584975P | 2012-01-10 | 2012-01-10 | |
| US61/584,975 | 2012-01-10 | ||
| US201261585799P | 2012-01-12 | 2012-01-12 | |
| US61/585,799 | 2012-01-12 | ||
| PCT/US2013/020195 WO2013106238A1 (en) | 2012-01-10 | 2013-01-04 | Leukotriene b4 antagonist compound |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015509917A JP2015509917A (ja) | 2015-04-02 |
| JP2015509917A5 true JP2015509917A5 (enExample) | 2016-01-14 |
Family
ID=47604162
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014552215A Withdrawn JP2015509917A (ja) | 2012-01-10 | 2013-01-04 | ロイコトリエンｂ４アンタゴニスト化合物 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9187411B2 (enExample) |
| EP (1) | EP2802557B1 (enExample) |
| JP (1) | JP2015509917A (enExample) |
| KR (1) | KR20140099546A (enExample) |
| CN (1) | CN104011012B (enExample) |
| AU (1) | AU2013208260A1 (enExample) |
| BR (1) | BR112014016450A2 (enExample) |
| CA (1) | CA2857521C (enExample) |
| EA (1) | EA023067B1 (enExample) |
| ES (1) | ES2571452T3 (enExample) |
| IN (1) | IN2014MN01014A (enExample) |
| MX (1) | MX2014008452A (enExample) |
| WO (1) | WO2013106238A1 (enExample) |
| ZA (1) | ZA201404732B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3383868B1 (en) | 2015-11-30 | 2022-10-05 | Merck Sharp & Dohme LLC | Aryl sulfonamides as blt1 antagonists |
| WO2017095722A1 (en) | 2015-11-30 | 2017-06-08 | Merck Sharp & Dohme Corp. | Aryl acylsulfonamides as blt1 antagonists |
| US10450309B2 (en) | 2015-11-30 | 2019-10-22 | Merch Sharp & Dohme Corp. | Aryl sulfonamides as BLT1 antagonists |
| US10370368B2 (en) | 2015-11-30 | 2019-08-06 | Merck Sharp & Dohme Corp. | Aryl acylsulfonamides as BLT1 antagonists |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5105017A (en) * | 1983-07-18 | 1992-04-14 | Eli Lilly And Company | Leukotriene antagonist intermediates |
| GB9027023D0 (en) | 1990-12-12 | 1991-01-30 | Wellcome Found | Anti-atherosclerotic aryl compounds |
| PH30449A (en) | 1991-11-25 | 1997-05-28 | Lilly Co Eli | Substituted phenyl phenol leukotriene antagonists |
| CN1035001C (zh) * | 1993-01-02 | 1997-05-28 | 伊莱利利公司 | 取代的苯基苯酚基白三烯拮抗物 |
| EP0743064A1 (en) * | 1995-05-17 | 1996-11-20 | Eli Lilly And Company | Leukotriene antagonists for use in the treatment or prevention of alzheimer's disease |
| AU6572298A (en) | 1997-03-21 | 1998-10-20 | Eli Lilly And Company | Leukotriene antagonists useful for treating ischemia reperfusion injury |
| EP1231939A2 (en) | 1999-11-11 | 2002-08-21 | Eli Lilly And Company | Oncolytic combinations for the treatment of cancer |
| WO2001034198A2 (en) | 1999-11-11 | 2001-05-17 | Eli Lilly And Company | Oncolytic combinations for the treatment of cancer |
| AU2001261832A1 (en) | 2000-05-09 | 2001-11-20 | Creighton University | Methods for inhibiting proliferation and inducing apoptosis in cancer cells |
| WO2001094333A2 (en) * | 2000-06-02 | 2001-12-13 | Eli Lilly & Company | Process for the preparation of benzoyl substituted bicyclic compounds and chiral benzopyran derivatives |
| BRPI0407180A (pt) | 2003-02-14 | 2006-02-07 | Lilly Co Eli | Composto, composição farmacêutica, métodos para modular um receptor ativado pelo proliferador de peroxissoma, para tratar ou prevenir uma doença ou condição, para diminuir a glicose no sangue em um mamìfero, para tratar ou prevenir diabetes mellitus, doença cardiovascular e sìndrome x em um mamìfero, e, uso de um composto |
-
2013
- 2013-01-04 KR KR1020147018769A patent/KR20140099546A/ko not_active Withdrawn
- 2013-01-04 EA EA201491099A patent/EA023067B1/ru not_active IP Right Cessation
- 2013-01-04 WO PCT/US2013/020195 patent/WO2013106238A1/en not_active Ceased
- 2013-01-04 ES ES13701305T patent/ES2571452T3/es active Active
- 2013-01-04 AU AU2013208260A patent/AU2013208260A1/en not_active Abandoned
- 2013-01-04 BR BR112014016450A patent/BR112014016450A2/pt not_active IP Right Cessation
- 2013-01-04 CN CN201380004537.9A patent/CN104011012B/zh not_active Expired - Fee Related
- 2013-01-04 EP EP13701305.8A patent/EP2802557B1/en active Active
- 2013-01-04 JP JP2014552215A patent/JP2015509917A/ja not_active Withdrawn
- 2013-01-04 MX MX2014008452A patent/MX2014008452A/es unknown
- 2013-01-04 CA CA2857521A patent/CA2857521C/en not_active Expired - Fee Related
- 2013-01-04 US US14/359,924 patent/US9187411B2/en not_active Expired - Fee Related
-
2014
- 2014-05-26 IN IN1014MUN2014 patent/IN2014MN01014A/en unknown
- 2014-06-26 ZA ZA2014/04732A patent/ZA201404732B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017537066A5 (enExample) | ||
| JP2012255026A5 (enExample) | ||
| JP2014515013A5 (enExample) | ||
| JP2013518107A5 (enExample) | ||
| JP2014507446A5 (enExample) | ||
| JP2015501783A5 (enExample) | ||
| JP2015512931A5 (enExample) | ||
| JP2013014622A5 (enExample) | ||
| JP2017513836A5 (enExample) | ||
| JP2013525444A5 (enExample) | ||
| JP2010521516A5 (enExample) | ||
| JP2016518337A5 (enExample) | ||
| JP2013519675A5 (enExample) | ||
| JP2013534248A5 (enExample) | ||
| JP2014521735A5 (enExample) | ||
| JP2014511891A5 (enExample) | ||
| JP2013032389A5 (enExample) | ||
| IL229199A (en) | N– (2– {2– dimethylaminoethyl-methylamino} –4 – methoxy-5 - {[4– (1-methylindol-3-yl) pyrimidine-2-yl] amino} phenyl) prop-2-anamide and salts acceptable in pharmacy Her, pharmaceuticals that include her and its use in the manufacture of cancer drugs | |
| JP2011518833A5 (enExample) | ||
| JP2012184234A5 (enExample) | ||
| JP2013523733A5 (enExample) | ||
| JP2012530705A5 (enExample) | ||
| JP2020097577A5 (enExample) | ||
| JP2011527299A5 (enExample) | ||
| JP2017508817A5 (enExample) |